- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
EU approves Gadovist for use in paediatric patients less than 2 years of age
14 July 2015 • Author: Victoria White
Bayer HealthCare’s Gadovist (gadobutrol) has received a label extension in the European Union (EU) for diagnostic use with magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA) in paediatric patients less than 2 years of age, including term newborns.
Country approvals by regulatory bodies across the EU will follow.
“This approval provides radiologists in Europe with an important diagnostic tool for use in the youngest paediatric population,” said Dr Gabriele Hahn, study investigator and radiologist, University of Dresden, Germany. “The study data confirm the safety profile, dose and efficacy of gadobutrol in young patients under the age of 2, including newborns.”
Safety profile of Gadovist in paediatric patients similar to that of older children and adults
The approval was based on an international multi-centre study showing that the pharmacokinetic and safety profiles of Gadovist in paediatric patients less than 2 years of age were similar to that of older children and adults at standard dose (0.1 mmol/kg), confirming that the same weight-based dosing of Gadovist can be used as in older children and adults. The expanded use is for existing approved contrast-enhanced MRI diagnostic imaging indications in older populations, for example contrast-enhanced MRA and MRI of the central nervous system (CNS), liver, kidneys and other regions of the whole body.
“To date there were only limited data regarding the use of gadolinium-based contrast agents in paediatric patients younger than 2 years of age available, and there has been a significant need to better understand how they work in the youngest of patients,” said Dr Christiane Pering, Chief Medical Officer (CMO) and Head of Innovation within Bayer HealthCare’s Medical Care division. “This study and authorisation by health authorities are important in supporting paediatric radiologists with an approved contrast agent for use in all their paediatric patients.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics